Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorazolamide-Zn(II) complex is a metal-based coordination compound developed for the treatment of glaucoma and ocular hypertension. It is formed by the interaction of the sulfonamide chlorazolamide (5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide) with zinc(II) ions. While the parent sulfonamide exhibits poor topical penetration and weak intraocular pressure (IOP) lowering effects, the zinc complex significantly enhances pharmacological activity and bioavailability in ocular tissues. The drug acts as a potent inhibitor of carbonic anhydrase (CA) isozymes, particularly CA II, which is essential for the secretion of aqueous humor. By inhibiting these enzymes in the ocular fluids and tissues, the complex effectively reduces IOP, as demonstrated in experimental animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorazolamide-Zn(II) complex.